East Windsor, NJ—Sabinsa has been granted a new patent granted in Mexico for Boswellin PS, its Boswellia serrata ingredient. Patent MX328842 is for a synergistic composition containing boswellic acids and polysaccharides from the Boswellia species for its property to downregulate pro-inflammatory markers, according to a press release from Sabinsa. This property of the composition was also awarded with a patent grant in Australia, Canada, Eurasia, and Taiwan.
“Inflammation is an underlying cause of many health conditions throughout the world,” said Dr. Muhammed Majeed, Founder and Chairman of Sabinsa, in the release. “By applying modern research to ancient Ayurvedic knowledge, Sabinsa has been able to provide natural solutions, including the Boswellin PS ingredient, to this common condition.”
Earlier this year, Sabinsa reported that the company has been granted three new patents in Canada, and has received an additional Natural Products Number (NPN) from Health Canada, bringing the company’s total number of products with health claims in Canada to 37.